The world's first one-stop transcatheter aortic combined surgery, the world's first permanently implantable rotator cuff reconstruction balloon surgery, the world's first plateau 5G remote laparoscopic robotic surgery, the world's first approved branched aortic stent graft, and the world's first drug-eluting stent with patented technology for precise targeted release drugs...... Turning over the innovation and development process of MicroPort Group, the "first case" is dazzling. Today, MicroPort has more than 500 products on the market and has entered more than 20,000 hospitals in more than 100 countries around the world.
Pudong, where the global headquarters of MicroPort Group is located. Since 1998, MicroPort Group has always been rooted in this area and is committed to the development of high-end innovative medical devices that are in the leading position in the industry. "As an innovative high-end medical device group, MicroPort has always adhered to innovation as one of its core values. In recent years, various high-tech enterprises in Zhangjiang, including MicroPort Group, have continued to innovate and achieve continuous results, largely thanks to Pudong's open, inclusive and shared environmental atmosphere, which is most evident from the ever-changing supply of institutional innovation. Jiang Lei, rotating co-chairman of the Greater China Executive Committee of MicroPort Group, said.
Institutional innovation helps enterprises flourish
Bovine pericardium is the main material for the surgical treatment of patients with valvular heart disease. The VitaFlow transcatheter aortic valve system launched by Shanghai MicroPort CardioFlow Medical Technology Co., Ltd. in 2019 is the first self-expanding bovine pericardial bioprosthetic valve product approved for marketing in China. However, after the product was launched, it once faced the problem of raw material shortage: on the one hand, the supply of domestic bovine pericardium was very limited, and patients had a large demand for domestic high-quality heart valve products, and the production of raw materials could not keep up with the increasing market demand;
How to help innovative products cross the "last mile" hurdle? The Shanghai Municipal Committee of the Chinese People's Political Consultative Conference (CPPCC) at the municipal and municipal levels and the Shanghai Special Office of the General Administration of Customs have taken this as a breakthrough in the innovation of domestic medical devices, and finally assisted enterprises in overcoming the difficulties in the import of raw materials.
In the third quarter of this year, Shanghai MicroPort Cardioflow Medical Technology Co., Ltd. submitted an application for import access to 2,000 pieces of bovine pericardium for processing to Shanghai Customs, which was approved by the General Administration of Customs. This is the first time that a domestic enterprise has been allowed to import bovine pericardium for processing and production. In the following fourth quarter, the attributes of the bovine pericardium import license were further regulated by the relevant administrative departments, and enterprises were also told that they could apply for and allow "processing and production" on demand.
In Pudong, the first pilot of various policies has provided development opportunities for the development of the group. For example, the single-channel ECG recorder of Shanghai Yuanxin Medical Technology Co., Ltd. is the first medical device product approved for marketing in accordance with the "Implementation Plan for the Pilot Work of the Medical Device Registrant System in the China (Shanghai) Pilot Free Trade Zone";
"From taking the lead in piloting the medical device registrant system, to promoting the implementation of the Yangtze River Delta sub-center for the evaluation of drugs and medical devices, to the continuous upgrading of the reform policy of the free trade zone, it has provided an important boost to the development of MicroPort Group. "These policies help companies better adhere to innovation and bring more high-quality and inclusive medical products and medical services to the world." ”
Innovation at the core
Bringing first-of-its-kind products and technologies to more corners of the globe
In the Future Park of Zhangjiang Science City, a number of medical "heavy weapons" were exhibited in the Shanghai Science and Technology Innovation Achievement Exhibition, including the "Toumai" laparoscopic surgical robot brought by Shanghai Minimally Invasive Medical Robot (Group) Co., Ltd. This is the first domestic four-arm endoscopic surgical robot approved for marketing in China, covering urology, general surgery, thoracic surgery, and gynecological difficult procedures. As of the beginning of November, the "Toumai" robot has completed more than 1,500 cases of assisted human clinical surgery in more than 60 hospitals in more than 60 hospitals in 21 provinces, autonomous regions and municipalities across the country, including urology, general surgery, thoracic surgery, gynecology, pediatrics, etc., crossing the threshold of large-scale surgery. Among the 1,500 surgeries completed, nearly 200 types of surgeries were involved, more than 1,100 cases of fourth-level difficult surgeries, and nearly 60 consecutive surgeries in a single day, and at the same time, Toumai also assisted in the exploration of more than 80 5G remote human clinical surgeries, with a success rate of 100% and more than 10 records of the world's first cases.
In the product map of MicroPort Group, "firsts" abound, and the pace of "innovation" has never stopped. On November 7 this year, the pre-market clinical study of the intravascular piezoelectric conductwire system developed by Shanghai MicroPort Melody Medical Technology Co., Ltd. was launched in Zhongshan Hospital affiliated to Fudan University, and the team of academician Ge Junbo successfully completed the first patient enrollment on the same day.
Up to now, MicroPort Group has more than 10,000 patents (applications), has won the China National Science and Technology Progress Award for 5 times and several provincial and ministerial science and technology progress awards, and a total of 30 products have entered the "green channel" of national innovative medical device registration.
At present, MicroPort Group takes the global headquarters in Pudong as the origin to accelerate the radiation of the Yangtze River Delta region. In fact, as early as 2015, MicroPort Group took a step from Shanghai to the Yangtze River Delta and established the "Suzhou MicroPort Park" in Suzhou to develop orthopedic business. Since then, MicroPort Group has made steady progress, built and opened the "Jiaxing MicroPort Park", and further optimized its layout in the Yangtze River Delta region. With the continuous optimization of resource allocation and the strengthening of collaborative innovation, a self-contained innovation chain, supply chain and industrial chain of MicroPort Group has gradually formed a self-contained triangular closed-loop ecosystem within 100 kilometers of the Yangtze River Delta region, which conveys power and vitality for the transformation of cutting-edge medical scientific and technological achievements and the evolution of emerging internal and external innovation bodies in the most direct and efficient way.
Jiang Lei said that we uphold the belief of "helping hundreds of millions of people on the earth to cross the 115-year-old lifeline healthily", and accelerate the promotion of innovative medical device products and disease solutions to more regions around the world to better serve local patients.